American Association for Cancer Research
00085472can183374-sup-211068_3_supp_5741471_px3n10.pdf (153.89 kB)

Supplementary Figure S4. from Genome-Wide CRISPR-Cas9 Screen Reveals Selective Vulnerability of ATRX-Mutant Cancers to WEE1 Inhibition

Download (153.89 kB)
journal contribution
posted on 2023-03-31, 03:24 authored by Junbo Liang, Hong Zhao, Bill H. Diplas, Song Liu, Jianmei Liu, Dingding Wang, Yan Lu, Qing Zhu, Jiayu Wu, Wenjia Wang, Hai Yan, Yi-Xin Zeng, Xiaoyue Wang, Yuchen Jiao

Figure S4. Sensitivity to AZD1775 in ATRX WT and KO PLC/PRF/5 cells after adjusting for differences in growth rates.


National Natural Science Foundation Fund

National Key Basic Research Program of China


Infection Diseases of China



The tumor suppressor gene ATRX is frequently mutated in a variety of tumors including gliomas and liver cancers, which are highly unresponsive to current therapies. Here, we performed a genome-wide synthetic lethal screen, using CRISPR-Cas9 genome editing, to identify potential therapeutic targets specific for ATRX-mutated cancers. In isogenic hepatocellular carcinoma (HCC) cell lines engineered for ATRX loss, we identified 58 genes, including the checkpoint kinase WEE1, uniquely required for the cell growth of ATRX null cells. Treatment with the WEE1 inhibitor AZD1775 robustly inhibited the growth of several ATRX-deficient HCC cell lines in vitro, as well as xenografts in vivo. The increased sensitivity to the WEE1 inhibitor was caused by accumulated DNA damage–induced apoptosis. AZD1775 also selectively inhibited the proliferation of patient-derived primary cell lines from gliomas with naturally occurring ATRX mutations, indicating that the synthetic lethal relationship between WEE1 and ATRX could be exploited in a broader spectrum of human tumors. As WEE1 inhibitors have been investigated in several phase II clinical trials, our discovery provides the basis for an easily clinically testable therapeutic strategy specific for cancers deficient in ATRX. ATRX-mutant cancer cells depend on WEE1, which provides a basis for therapeutically targeting WEE1 in ATRX-deficient cancers.See related commentary by Cole, p. 375